Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment of carbapenem-resistantPseudomonas aeruginosainfections: a case for cefiderocol
Rafael Cantón, Yohei Doi, Patricia J. Simner
Expert Review of Anti-infective Therapy (2022) Vol. 20, Iss. 8, pp. 1077-1094
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Multidrug-resistant Gram-negative bacterial infections
Nenad Macesic, Anne‐Catrin Uhlemann, Anton Y. Peleg
The Lancet (2025) Vol. 405, Iss. 10474, pp. 257-272
Closed Access | Times Cited: 1
Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program
Michael J. Satlin, Patricia J. Simner, Christine M Slover, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 7
Open Access | Times Cited: 24
In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations
Anne Santerre Henriksen, Katy Jeannot, Antonio Oliver, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 11
Molecular analysis of metallo-beta-lactamase-producing Pseudomonas aeruginosa in Switzerland 2022–2023
Jacqueline Findlay, Otávio Hallal Ferreira Raro, Laurent Poirel, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2024) Vol. 43, Iss. 3, pp. 551-557
Open Access | Times Cited: 4
Computational investigation of amide derivative as potential anti-carbapenem-resistant Pseudomonas aeruginosa
Sopuruchukwu E. Ogbodo, Osarob U. Edeghor, Chioma U. Benson, et al.
Journal of the Indian Chemical Society (2024) Vol. 101, Iss. 8, pp. 101184-101184
Closed Access | Times Cited: 4
Neonatal sepsis due to NDM-1 and VIM-2 co-producing Pseudomonas aeruginosa in Morocco
Dina Daaboul, Marwan Osman, Issmat I. Kassem, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 7, pp. 1614-1618
Closed Access | Times Cited: 4
Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline
Najma Arshad, Wael Azzam, Marya D. Zilberberg, et al.
Microorganisms (2025) Vol. 13, Iss. 2, pp. 356-356
Open Access
Antipseudomonal cephalosporins versus piperacillin/tazobactam or carbapenems for the definitive antibiotic treatment of Pseudomonas aeruginosa bacteraemia: new kids on the ICU block?
Davide Fiore Bavaro, Giuseppe Accurso, Silvia Corcione, et al.
Journal of Antimicrobial Chemotherapy (2025)
Closed Access
Ceftazidime-avibactam plus aztreonam cocktail for the treatment of VIM-producing Pseudomonas aeruginosa infections: good enough to have another?
Manuel Pina‐Sánchez, Marta Covela Rúa, Carla López-Causapé, et al.
Journal of Antimicrobial Chemotherapy (2025)
Open Access
Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant Gram-negative bacteria
Carmen de la Fuente, Marina Rodríguez, N. Merino, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 1, pp. 106818-106818
Closed Access | Times Cited: 11
Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients
Carla López-Causapé, Ainhize Maruri-Aransolo, María A. Gomis-Font, et al.
Clinical Microbiology and Infection (2022) Vol. 29, Iss. 4, pp. 538.e7-538.e13
Open Access | Times Cited: 17
In vitro activities of ceftazidime–avibactam, ceftolozane–tazobactam, meropenem–vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012–2021
Yu-Lin Lee, Wen‐Chien Ko, Po‐Ren Hsueh
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 2, pp. 106867-106867
Closed Access | Times Cited: 10
Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye
Ecem Büyükyanbolu, Leyla Genc, Elizabeth A Cyr, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2024) Vol. 43, Iss. 9, pp. 1787-1794
Closed Access | Times Cited: 3
Antibacterial spectrum of cefiderocol
Desirée Cordero, Juan Antonio Castillo-Polo, Patricia Ruíz-Garbajosa, et al.
Revista Española de Quimioterapia (2022) Vol. 35, Iss. Suppl2, pp. 20-27
Open Access | Times Cited: 12
Understanding resistance acquisition by Pseudomonas aeruginosa and possible pharmacological approaches in palliating its pathogenesis
Mony Thakur, Khushboo, Yatin Kumar, et al.
Biochemical Pharmacology (2023) Vol. 215, pp. 115689-115689
Closed Access | Times Cited: 7
bla KPC-2 overexpression and bla GES-5 carriage as major imipenem/relebactam resistance mechanisms in Pseudomonas aeruginosa high-risk clones ST463 and ST235, respectively, in China
Yue Li, Fang Li, Mengqian Dong, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 11
Open Access | Times Cited: 7
Use of Cefiderocol in the Management of Children With Infection or Colonization With Multi-drug Resistant Gram-negative Bacteria: A Retrospective, Single-center Case Series
Hanna Schmid, Li‐An K. Brown, Bairavi Indrakumar, et al.
The Pediatric Infectious Disease Journal (2024) Vol. 43, Iss. 8, pp. 772-776
Closed Access | Times Cited: 2
The Challenge of Treating Infections Caused by Metallo‐β‐Lactamase–Producing Gram-Negative Bacteria: A Narrative Review
Carmen Hidalgo‐Tenorio, Germán Bou, Antonio Oliver, et al.
Drugs (2024)
Open Access | Times Cited: 2
A review of recent advances in the treatment of adults with complicated urinary tract infection
Emanuele Rando, Francesca Giovannenze, Rita Murri, et al.
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 9, pp. 1053-1066
Closed Access | Times Cited: 11
The primary pharmacology of ceftazidime/avibactam: resistancein vitro
Wright W. Nichols, Sushmita D. Lahiri, Patricia A. Bradford, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 3, pp. 569-585
Open Access | Times Cited: 6
The role of cefiderocol in clinical practice
Emilio Maseda, Alejandro Suárez-de-la-Rica
Revista Española de Quimioterapia (2022) Vol. 35, Iss. Suppl2, pp. 39-44
Open Access | Times Cited: 8
Candent issues in pneumonia. Reflections from the Fifth Annual Meeting of Spanish Experts 2023
C. Rodriguez-Leal, Carlos González‐Corralejo, Francisco Javier Candel, et al.
Revista Española de Quimioterapia (2024) Vol. 37, Iss. 3, pp. 221-251
Open Access | Times Cited: 1
Assessing the impact of meropenem exposure on ceftolozane/tazobactam-resistance development in Pseudomonas aeruginosa using in vitro serial passage
Aliaa Fouad, Samantha Nicolau, Pranita D. Tamma, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 5, pp. 1176-1181
Closed Access | Times Cited: 1
Pharmacokinetics, Safety and Tolerability of Single-dose or Multiple-dose Cefiderocol in Hospitalized Pediatric Patients Three Months to Less Than Eighteen Years Old With Infections Treated With Standard-of-care Antibiotics in the PEDI-CEFI Phase 2 Study
John S. Bradley, Elaine Orchiston, Simon Portsmouth, et al.
The Pediatric Infectious Disease Journal (2024)
Closed Access | Times Cited: 1
Molecular epidemiology and carbapenem resistance mechanisms of Pseudomonas aeruginosa isolated from a hospital in Fujian, China
Xueqin Xie, Zhou Liu, Jingyan Huang, et al.
Frontiers in Microbiology (2024) Vol. 15
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top